U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07288112) titled 'DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma' on Dec. 03.
Brief Summary: The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded with antigens from the patient's tumor in the form of tumor lysate and mRNA. The goal is to stimulate a T cell immune response that eliminates tumor cells.
The study consists of two components: an initial phase I safety study to confirm safety/tolerability of the treatment regimen, and, subsequently, a single...